SCHEMBL806164

SCHEMBL806164

CC(=O)CCCCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420548 1.00 PAOX (1.00)
SCHEMBL13082344 1.00 PAOX (1.00)
SCHEMBL3318566 1.00 PAOX (1.00)
SCHEMBL12658620 1.00 PAOX (1.00)
SCHEMBL9623780 1.00 PAOX (1.00)
SCHEMBL23872982 1.00 PAOX (1.00)
SCHEMBL18726287 1.00 PAOX (1.00)
SCHEMBL16297742 1.00 PAOX (1.00)
SCHEMBL18533504 1.00 PAOX (1.00)
Water SCHEMBL5510156 0.97 PAOX (0.95)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114958291-B Single-component high-adhesion room temperature vulcanized organosilicon sealant and preparation method thereof 北京航空材料研究院股份有限公司 2023-07-04 CN claimed
WO-2024133382-A1 GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 WO disclosed
US-20230357300-A1 TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS ADJUVANCE TECHNOLOGIES, INC. (US) 2023-11-09 US disclosed
US-20230357300-A1 TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS ADJUVANCE TECHNOLOGIES, INC. (US) 2023-11-09 US disclosed
WO-2023205272-A1 PYRAZINAMIDE COMPOUNDS THE GENERAL HOSPITAL CORPORATION (US) 2023-10-26 WO disclosed
US-11786603-B2 Optimized transglutaminase site-specific antibody conjugation REGENERON PHARMACEUTICALS, INC. (US) 2023-10-17 US disclosed
CN-116850132-A Formulations of active agents for oral administration 安提拉生物有限公司 2023-10-10 CN disclosed
CN-116831978-A Formulations of active agents for oral administration 安提拉生物有限公司 2023-10-03 CN disclosed
CN-116831977-A Formulations of active agents for oral administration 安提拉生物有限公司 2023-10-03 CN disclosed
CN-116790223-A Single-component high-adhesion dealcoholized room temperature vulcanized organosilicon sealant and preparation method thereof 北京航空材料研究院股份有限公司 2023-09-22 CN disclosed
US-20070287670-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-12-13 US disclosed
WO-2007092363-A2 HYBRID SLIP CASTING-ELECTROPHORETIC DEPOSITION (EPD) PROCESS SAN DIEGO STATE UNIVERSITY (US) 2007-08-16 WO disclosed
US-7238670-B2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
US-7238670-B2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
WO-2007058989-A2 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 US disclosed
WO-2006102069-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS MICROBIA, INC. (US) 2006-09-28 WO disclosed
US-6872827-B2 Somatostatin analogue compounds CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2005-03-29 US disclosed
WO-2004094461-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 WO disclosed
WO-2003033671-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-24 WO disclosed